Latest Articles

Publication Date
Milena Cassani to represent Algarve in Miss Portugal final - The Portugal News

Milena Cassani to represent Algarve in Miss Portugal final The Portugal News

Published: July 17, 2026, 11:36 a.m.
A Vancouver teen's mission to bring endometriosis education to schools - Vancouver Is Awesome

A Vancouver teen's mission to bring endometriosis education to schools Vancouver Is Awesome

Published: July 17, 2026, 9:05 a.m.
A Vancouver teen's mission to bring endometriosis education to schools - North Shore News

A Vancouver teen's mission to bring endometriosis education to schools North Shore News

Published: July 17, 2026, 3 a.m.
Laparoscopic Assisted Neo-Cervico-Vaginal Anastomosis by Rail-Road Procedure In Cervico-Vaginal Atresia.

Cervico-vaginal atresia is a rare entity, difficult to diagnose and treat, with a higher rate of complications. It is classified as type 1b mullerian anomaly per ASRM and subclass C4 …

Published: July 17, 2026, midnight
A Vancouver Teen’s Mission to Bring Endometriosis Education to Schools - Niagara Falls Review

A Vancouver Teen’s Mission to Bring Endometriosis Education to Schools Niagara Falls Review

Published: July 16, 2026, 7:32 p.m.
A Vancouver Teen’s Mission to Bring Endometriosis Education to Schools - Penticton Herald

A Vancouver Teen’s Mission to Bring Endometriosis Education to Schools Penticton Herald

Published: July 16, 2026, 7:32 p.m.
A Vancouver Teen’s Mission to Bring Endometriosis Education to Schools - St. Catharines Standard

A Vancouver Teen’s Mission to Bring Endometriosis Education to Schools St. Catharines Standard

Published: July 16, 2026, 3:47 p.m.
A Vancouver Teen’s Mission to Bring Endometriosis Education to Schools - The Tyee

A Vancouver Teen’s Mission to Bring Endometriosis Education to Schools The Tyee

Published: July 16, 2026, 4:19 a.m.
Rheumatic Heart Disease: Inflammation, Immune Pathways, Valve Remodeling, and the Promise of SGLT2 Inhibitors.

Rheumatic heart disease (RHD) remains the leading cause of acquired valvular heart disease in low- and middle-income countries, affecting an estimated 40 million individuals and disproportionately affecting children and young …

Published: July 16, 2026, midnight
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!